Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2002

View Archived Issues

Positive phase I results for AGI-1096 in prevention of transplant rejection

Amgen files sBLA for Enbrel for improvement of physical function in RA

Theratechnologies adds GLP-1 program to portfolio, signs development agreement with Alza

Final phase I results for Antrin phototherapy in coronary artery disease

Phase I/II interim analysis of Targretin in chronic severe hand dermatitis

Cholestagel MAA filed for primary hypercholesterolemia

NicOx signs exclusive agreement with AstraZeneca for AZD-3582 and other CINODs in Japan

GPI-1485 shows neuroprotective activity in preclinical models of postprostatectomy ED

ISV-401 safe and effective in acute bacterial conjunctivitis

Monoclonal antibodies targeting human BST2

Anti-MRSA cephalosporin and prodrug presented at ICAAC meeting

Potent and broad-spectrum antifungal activity in a series of thiotriazolones

Quinolone-linked oxazolidinones investigated at Morphochem

Korean researchers identify potent parenteral cephalosporin for resistant infections

Phase III interim findings for protease inhibitor GW-433908 discussed in San Diego

Marketing approval granted for first aldosterone blocker in high blood pressure

MGI Pharma/Helsinn seek FDA approval for new CINV therapy

Thrombopoietin agonists prepared and tested at Shionogi

Novartis designs new DPP-IV inhibitors for diabetes mellitus

Toyama researchers identify novel agents for cerebral ischemic disorders

Novel immunosuppressants in early development at Sumitomo

Venantius claims mast cell-stabilizing agents for inflammatory disorders

Novel inhibitors of TNF-alpha and/or IL-1beta production described in Sankyo patent

Long-term survival data for Gliadel Wafer in brain cancer

Allovectin-7 update

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...